NEW YORK, June 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding athenahealth, Inc. (NASDAQ: ATHN), Dun & Bradstreet Corp. (NYSE: DNB), Veeva Systems Inc. (NYSE: VEEV), Medidata Solutions, Inc. (NASDAQ: MDSO) and WebMD Health Corp. (NASDAQ: WBMD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3174-100free.
athenahealth, Inc. Analyst Notes
On May 28, 2014, athenahealth, Inc. (athenahealth) announced its 2014 PayerView® Report that delivers insight into the provider-payer relationship. The Company stated that Humana ranked 1st in overall performance amongst 148 payers for the second year in a row. The 2014 PayerView results rank commercial and government health insurers according to specific measures of financial, administrative, and transactional performance. Insights from the 2014 report revealed the following trends: Medicaid performed worse than commercial plans and Medicare on key metrics; Provider collection burden, measured as the percent of charges transferred from the primary insurer to the next responsible party after the time of service, is increasing slightly; Blue Cross Blue Shield plans reimburse providers most quickly; and Commercial payers offer the most efficient enrollments. The full analyst notes on athenahealth are available to download free of charge at:
http://www.analystsreview.com/ATHN.pdf/Register
Dun & Bradstreet Corp. Analyst Notes
On May 28, 2014, Dun & Bradstreet Corp. (Dun & Bradstreet) stock declined 2.82% to end the day at $103.72. The Company's stock rose 0.55% during the past five trading days compared to the Dow Jones Industrial Average which rose 1.58% and to S&P 500 which went up 1.97% during the same trading period. The full analyst notes on Dun & Bradstreet are available to download free of charge at:
http://www.analystsreview.com/DNB.pdf/Register
Veeva Systems Inc. Analyst Notes
On May 20, 2014, Veeva Systems, Inc. (Veeva) announced that it is partnering with Symphony Health Solutions for simplifying the use of the combination of Veeva's rich healthcare professional (HCP) and healthcare organization (HCO) data with Symphony Health Solutions' leading performance data and analytical insights for life sciences companies. "By coming together and aligning our datasets, we are breaking down industry barriers for our joint customers," said Peter Gassner, CEO, Veeva. "We are eliminating their time, effort, and expense to deliver the complete and accurate information needed to optimize their commercial operations." The Veeva Network customer master pre-mapped with Symphony Health Solutions data is anticipated to be available in Q3 2014. Thefull analyst notes on Veeva are available to download free of charge at:
http://www.analystsreview.com/VEEV.pdf/Register
Medidata Solutions, Inc. Analyst Notes
On May 20, 2014, Medidata Solutions, Inc. (Medidata) announced a partnership with TransCelerate BioPharma Inc. (TransCelerate) on a project that aims to inform of nonprofit organization's continued efforts to modernize and streamline the way clinical trials are conducted and monitored worldwide. Through the Medidata Clinical Cloud', Medidata is providing metrics and analytics to help TransCelerate answer important questions posed by the industry regarding the benefits and challenges associated with a risk-based approach to monitoring of clinical trial sites. "Medidata shares TransCelerate's commitment to modernizing clinical trials in order to speed up the delivery of safe, new therapies to patients," said Glen de Vries, Medidata's President. "We are thrilled to work with TransCelerate and delighted to help the consortium leverage our rich data and analytics capabilities." The full analyst notes on Medidata Solutions are available to download free of charge at:
http://www.analystsreview.com/MDSO.pdf/Register
WebMD Health Corp. Analyst Notes
On May 28, 2014, WebMD Health Corp. (WebMD) stock increased 0.98% to end the day at $43.47. The Company's stock increased 4.22% over the past three trading days compared to the Nasdaq Composite which rose 1.70% during the same trading period. The full analyst notes on WebMD are available to download free of charge at:
http://www.analystsreview.com/WBMD.pdf/Register
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
